Existence of direct infringement is a prerequisite of induced infringement but is not a proof of it. gV sales could be 30% of the market without liability of Hikma. Again the volume / % does not matter ... it is just a quantity ... the issue is a "quality": Hikma's action fall within inducement category or does not (it could fall with 1 script ...)
Exactly ... We know some entity is responsible for infringement - and AMRN will work down the line to insurers and pharmacy supply chains etc and that is where the parties responsible for infringement will be found - in the long run it doesnt matter who is responsible for infringement all that matters is that it is found - that it ceases - that the US market is restored ... which is going to happen and is why after doubling my money in several months I have decided not to sell - I do see another doubling if not tripling